Biotechnology company Genentech, part of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), revealed on Thursday that its Phase II/III SKYSCRAPER-06 trial testing a combination therapy for lung cancer did not meet its primary goals.
The treatment, tiragolumab plus Tecentriq and chemotherapy, showed reduced effectiveness compared to the standard treatment.
While the safety profile remained acceptable, Genentech will halt the trial due to these disappointing efficacy results. The company will inform patients and investigators, share findings with health authorities and present them at a medical conference.
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
PureTech Health highlights progress in IPF research and LYT-100 at CHEST 2024
MediLink enters clinical trial collaboration and supply agreement with Amgen
Innovent Biologics partners with Jiangsu Aosaikang Pharmaceutical for lung cancer treatment
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Liquidia and Pharmosa expand collaboration for inhaled treprostinil
Alvotech launches confirmatory study for Entyvio biosimilar
Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers
Innate Pharma receives FDA clearance of IND for IPH4502, a Nectin-4 targeting ADC for solid tumours
Intas Pharmaceuticals reports positive opinion for HETRONIFLY in Europe
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial